UBS (Lux) Equity Fund - Biotech (USD) (SEK) P-acc

Reference Data

ISIN LU1991432631
Valor Number 47685912
Bloomberg Global ID UBSBIPA LX
Fund Name UBS (Lux) Equity Fund - Biotech (USD) (SEK) P-acc
Fund Provider UBS Asset Management Switzerland AG 8098 Zürich, Schweiz
E-Mail: ubs-am-wholesale-switzerland@ubs.com
Web: www.ubs.com/fonds
Fund Provider UBS Asset Management Switzerland AG
Representative in Switzerland UBS Fund Management (Switzerland) AG
Basel
Phone: +41 61 288 49 10
Distributor(s) UBS Global Asset Management
Basel
Phone: +41 61 288 20 20
Asset Class Equities
EFC Category Equity Global Advanced Markets
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations.
Peculiarities

Fund Prices

Current Price * 957.28 SEK 17.12.2024
Previous Price * 951.13 SEK 16.12.2024
52 Week High * 1,083.35 SEK 29.07.2024
52 Week Low * 863.24 SEK 20.12.2023
NAV * 957.28 SEK 17.12.2024
Issue Price * 957.28 SEK 17.12.2024
Redemption Price * 957.28 SEK 17.12.2024
Closing Price *
Indicative Minimum Price
Fund Assets *** 4,773,897,053
Unit/Share Assets *** 77,298,586
Trading Information SIX

Performance

YTD Performance +3.70% 29.12.2023
17.12.2024
YTD Performance (in CHF) +1.38% 29.12.2023
17.12.2024
1 month +3.55% 18.11.2024
17.12.2024
3 months -2.31% 17.09.2024
17.12.2024
6 months +0.12% 17.06.2024
17.12.2024
1 year +8.10% 18.12.2023
17.12.2024
2 years +1.17% 19.12.2022
17.12.2024
3 years +6.91% 17.12.2021
17.12.2024
5 years +20.32% 17.12.2019
17.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Vertex Pharmaceuticals Inc 9.34%
Alnylam Pharmaceuticals Inc 6.68%
Neurocrine Biosciences Inc 5.37%
Guardant Health Inc 4.39%
Amgen Inc 4.25%
Regeneron Pharmaceuticals Inc 4.23%
Moderna Inc 3.85%
AbbVie Inc 3.78%
Denali Therapeutics Inc 3.67%
Roivant Sciences Ltd Ordinary Shares 3.57%
Last data update 30.11.2024

Cost / Risk

TER 2.10%
TER date 30.11.2023
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 1.63%
Ongoing Charges *** 2.10%
SRRI ***
SRRI date *** 30.11.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)